The process exploits the cell's efficient endogenous DNA replication and repair pathways to precisely correct the gene defect in situ. The main objective of this research project is to evaluate the utility of this non-viral gene therapy strategy in correcting inherited metabolic gene defects of liver ornithine transcarbamylase (OTC) both in utero and in the neonate. This objective tests our hypothesis that correction of the mutant gene in livers of affected sparse fur/ash (spf/ash) mice will improve the phenotype associated with the disease. The first specific aim is designed to evaluate SSO-mediated correction of the point mutation for OTC deficiency in adult and fetal hepatocytes isolated from the spfas"""""""" mouse, as well as Chinese hamster ovary (CHO) cells expressing a human R40H OTC mutant gene. A number of different SSO designs will be tested as well as non-viral polycation and nanocapsule delivery systems developed for use in vitro and in vivo. The second specific aim is designed to characterize the potential of SSOs for correcting the OTC deficiency of spf/ash mice by in utero and neonatal gene therapy. Genomic repair of the OTC point mutation in liver will be determined as well as the relevant metabolic parameters for OTC expression. The efficiency of in situ genomic correction will be correlated with changes in phenotype. Long-term studies will establish the stability of the corrected mutation in both quiescent and replicating hepatocytes after partial hepatectomy. In addition, we will optimize the dosing regimen, as well as the delivery vehicle, route and time of administration. Detailed short-and long-term toxicity/pathology profiles will be established to determine any potential adverse effects from either the delivery systems or oligonucleotides. These studies will provide novel and important new information on the potential problems and applications in using this non-viral strategy to genetically correct gene defects in utero. In addition, it will provide greater insight into the susceptibility of specific human mutations to site- specific gene repair. The long term goal of this research proposal is to develop, (i) optimal parameters for therapeutic correction of single base mutations in liver using non-viral strategies, and (ii) methods of neonatal and in utero gene correction for application to OTC and other inborn errors of metabolism in liver. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK067436-02
Application #
7478101
Study Section
Gastrointestinal Cell and Molecular Biology Study Section (GCMB)
Program Officer
Doo, Edward
Project Start
2007-08-06
Project End
2012-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$298,808
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Trembley, Janeen H; Kren, Betsy T; Abedin, Md Joynal et al. (2017) CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer. Pharmaceuticals (Basel) 10:
Cannon, Claire M; Trembley, Janeen H; Kren, Betsy T et al. (2017) Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer. Hum Gene Ther Clin Dev 28:80-86
Ahmed, Khalil; Kren, Betsy T; Abedin, Md Joynal et al. (2016) CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. Oncotarget 7:61789-61805
Kren, Betsy T; Unger, Gretchen M; Abedin, Md J et al. (2015) Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast Cancer Res 17:19
Unger, Gretchen M; Kren, Betsy T; Korman, Vicci L et al. (2014) Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol Cancer Ther 13:2018-29
Trembley, Janeen H; Unger, Gretchen M; Korman, Vicci L et al. (2014) Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. PLoS One 9:e109970
Trembley, Janeen H; Unger, Gretchen M; Gomez, Omar Cespedes et al. (2014) Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation. Mol Cell Pharmacol 6:15-25
Trembley, Janeen H; Unger, Gretchen M; Korman, Vicci L et al. (2012) Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett 315:48-58
Shu, Jingmin; Kren, Betsy T; Xia, Zhilian et al. (2011) Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology 54:609-19
Sjeklocha, Lucas; Chen, Yixin; Daly, Meghan C et al. (2011) ?-globin matrix attachment region improves stable genomic expression of the Sleeping Beauty transposon. J Cell Biochem 112:2361-2375

Showing the most recent 10 out of 17 publications